Overview

* Cerus ( CERS ) Q2 total revenue rises 19% yr/yr to $60.1 mln, beating estimates, per LSEG data

* Q2 product revenue up 16% yr/yr to $52.4 mln, driven by IFC and platelet sales

* Co raises full-year 2025 product revenue guidance to $200 mln - $203 mln

Outlook

* Cerus ( CERS ) raises full-year 2025 product revenue guidance to $200 mln-$203 mln

* Company increases 2025 IFC revenue guidance to $16 mln-$18 mln

* Cerus ( CERS ) expects positive full-year 2025 non-GAAP adjusted EBITDA

* Company anticipates continued growth in second half of 2025

Result Drivers

* IFC DEMAND - Strong demand for INTERCEPT Fibrinogen Complex drove product revenue growth, with Q2 revenue rising to $5.6 mln from $2.0 mln year-ago

* INT200 DEVICE - Successful launch and adoption of the new LED-based INT200 illumination device exceeded performance expectations, per CEO

* GOVERNMENT CONTRACTS - Increase in government contract revenue was driven by R&D activities for the INTERCEPT RBC program and next-gen pathogen reduction technology

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $60.10 $54.40

Revenue mln mln (4

Analysts

)

Q2 Net -$5.70

Income mln

Q2 Miss $900,000 $2.12

Adjusted mln (3

EBITDA Analysts

)

Q2 Gross 55.2%

Margin

Q2 Gross $29 mln

Profit

Q2 $40.10

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Cerus Corp ( CERS ) is $5.00, about 74% above its August 4 closing price of $1.30

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)